Compare Biogen Inc (BIIB) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Indonesia Energy Corporation Limited — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Indonesia Energy Corporation Limited trades at $2.92 (market cap $45.55M). The key difference: Biogen Inc is far larger — about 661.5× Indonesia Energy Corporation Limited's market cap, and Biogen Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| BIIB | INDO | |
|---|---|---|
Market Cap | $30.13B | $45.55M |
Sector | Health | Energy |
52-Week High | $216.63 | $6.74 |
52-Week Low | $128.93 | $2.49 |
Enterprise Value | $37.20B | $40.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Indonesia Energy Corporation (INDO) trades at $2.93, up 0.34% with a bullish technical signal. The stock shows negative profitability metrics including -253.4% net income margin and -26.95% ROE, though recent drilling operations at the Kruh Block indicate operational progress. Analyst consensus is unanimously bullish with 3 buy ratings. Technical indicators show bullish moving averages and neutral oscillators with RSI at 60.28.
While current fundamentals show significant losses, the company's active drilling program and 100% analyst buy rating suggest potential upside if operational execution improves. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative potential for investors comfortable with high-risk energy exploration plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
